| 1.51 -0.11 (-6.79%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.15 | 1-year : | 2.5 |
| Resists | First : | 1.84 | Second : | 2.14 |
| Pivot price | 1.5  |
|||
| Supports | First : | 1.37 | Second : | 1.13 |
| MAs | MA(5) : | 1.53  |
MA(20) : | 1.57 |
| MA(100) : | 2.02 |
MA(250) : | 2.03 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 53.5 |
D(3) : | 42.3 |
| RSI | RSI(14): 42.8 |
|||
| 52-week | High : | 3.4 | Low : | 1.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALEC ] has closed below upper band by 45.6%. Bollinger Bands are 67.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.62 - 1.63 | 1.63 - 1.64 |
| Low: | 1.47 - 1.48 | 1.48 - 1.48 |
| Close: | 1.5 - 1.51 | 1.51 - 1.52 |
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Sat, 01 Aug 2026
Enterprise value to EBITDA forward of Alector, Inc. – NASDAQ:ALEC - tradingview.com
Fri, 31 Jul 2026
Alector Inc (ALEC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Wed, 29 Jul 2026
ALEC|Alector Inc|Price:1.640|Chg%:+0.120 - TradingKey
Tue, 28 Jul 2026
ALEC|Alector Inc|Price:1.515|Chg%:+0.005 - TradingKey
Fri, 24 Jul 2026
Alector, Inc. Revenue Breakdown – NASDAQ:ALEC - tradingview.com
Sun, 19 Jul 2026
Alector, Inc. (NASDAQ:ALEC) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 111 (M) |
| Held by Insiders | 9.38e+007 (%) |
| Held by Institutions | 9.6 (%) |
| Shares Short | 5,250 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2749e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 382.3 % |
| Return on Equity (ttm) | -25.8 % |
| Qtrly Rev. Growth | 1.842e+007 % |
| Gross Profit (p.s.) | -119.17 |
| Sales Per Share | -398.09 |
| EBITDA (p.s.) | -1.481e+008 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -173 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 10.06 |
| Dividend | 0 |
| Forward Dividend | 5.66e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|